Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.

Molecular medicine (Cambridge, Mass.) - 16 Jan 2023

Luo Mayao, Zhang Yifan, Xu Zhuofan, Lv Shidong, Wei Qiang, Dang Qiang

Abstract excerpt

BACKGROUND: Bladder cancer (BCa) is the most common malignant tumor of the urinary system, with transitional cell carcinoma (TCC) being the predominant type. EP300 encodes a lysine acetyltransferase that regulates a large subset of genes by acetylating histones and non-histone proteins. We previously identified several bladder cancer-associated mutations in EP300 using high-throughput sequencing; however, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to E1A-Associated p300 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histones

Share to Mutation

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36647005
DOI: 10.1186/s10020-023-00608-7
PMCID: PMC9843983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.PMID 36647005Read ↗

EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.Semantic proximity Read ↗

Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder CancerSemantic proximity Read ↗

Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome SequencingSemantic proximity Read ↗

Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise.Semantic proximity Read ↗

Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.Semantic proximity Read ↗

Bladder malignant granular cell tumor with EP300 gene mutation: a case report and literature reviewSemantic proximity Read ↗

Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.Semantic proximity Read ↗

EP300 as an oncogene correlates with poor prognosis in esophageal squamous carcinomaSemantic proximity Read ↗

Core promoter mutation contributes to abnormal gene expression in bladder cancer.Semantic proximity Read ↗

Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.Semantic proximity Read ↗

Therapeutic significance of ARID1A mutation in bladder cancer.Semantic proximity Read ↗

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.